Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data

European Journal of Clinical Pharmacology

Volumn 70, Issue 2, 2014, Pages 167-178

  Nordmark, Anna ^a,b   Andersson, Anita ^a   Baranczewski, Pawel ^a   Wanag, Ewa ^a   Ståhle, Lars ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

AZD2066; Cocktail study; CYP2C9; Drug drug interactions; In vitro; PBPK

Indexed keywords

ADULT; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; ISOXAZOLES; MALE; MICROSOMES, LIVER; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTOR, METABOTROPIC GLUTAMATE 5; TRIAZOLES; YOUNG ADULT;

EID: 84895074177     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1603-8     Document Type: Article

References (43)

1. Food and Drug Administration (2012) Draft guidance for industry - drug interaction studies, study design, data analysis, implications for dosing, and labeling recommendations. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed: 28 Aug 2012
2. European Medicines Agency (2012) Guideline on the investigations of drug interactions. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2012/07/WC500129606.pdf. Accessed 23 Aug 2012
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA, Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443-469
4. Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT, Houston JB, Galetin A (2011) Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol 71:72-87
5. Rowland M, Peck C, Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45-73
6. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, Wu TC, Booth BP, Rahman NA, Reynolds KS, Gil Berglund E, Lesko LJ, Huang SM (2011) Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89:259-267
7. Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B (2011) AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 26:1243-1250
8. Levenga J, Hayashi S, de Vrij FM, Koekkoek SK, van der Linde HC, Nieuwenhuizen I, Song C, Buijsen RA, Pop AS, Gomezmancilla B, Nelson DL, Willemsen R, Gasparini F, Oostra BA (2011) AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis 42:311-317
9. Rohof WO, Lei A, Hirsch DP, Ny L, Astrand M, Hansen MB, Boeckxstaens GE (2012) The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Aliment Pharmacol Ther 35:1231-1242
10. Jonzon B, Butler S, Karlsten R, Malamut R, Ståhle L, Huizar K, Stacey B (2012) Efficacy and safety of the mGluR5 antagonist AZD2066 in peripheral neuropathic pain patients with mechanical hypersensitivity (NPMH): results of a phase IIa randomised, double-blind, placebo-controlled study PT 427, 14th World Congress of Pain, IAPS
11. Karlsten R, Malamut R, Jonzon B, Ståhle L, Huizar K, Argoff C (2012) Efficacy and safety of the mGluR5 antagonist AZD2066 in painful diabetes neuropathy (PDN): results of a phase IIa randomised, double-blind, placebo-controlled study PT 429, 14th World Congress of Pain, IAPS
12. Ståhle L, Karlsten R, Jonzon B, Eriksson B, Kågedal M, Dominicus A (2012) Safety evaluation of the mGluR5 antagonists AZD9272, AZD2066 and AZD2516 in healthy volunteers and patients with neuropathic pain or major depressive disorder PT 444, 14th World Congress of Pain, IAPS
13. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A (2009) The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211-223
14. Blakey GE, Lockton JA, Perrett J, Norwood P, Russell M, Aherne Z, Plume J (2004) Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. Br J Clin Pharmacol 57:162-169
15. Brandt RB, Laux JE, Yates SW (1987) Calculation of inhibitor Ki and inhibitor type from the concentration of inhibitor for 50% inhibition for Michaelis-Menten enzymes. Biochem Med Metab Biol 37:344-349
16. Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, Shin JG (2007) Development of the «Inje cocktail» for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther 82:531-540
17. Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS Jr (2000) Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the «Cooperstown cocktail». Clin Pharmacol Ther 68:375-383
18. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS Jr (2003) Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase- 2, and xanthine oxidase activities with the «Cooperstown 5+1 cocktail». Clin Pharmacol Ther 74:437-447
19. Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yasar U, Bertilsson L (2003) The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 73:517-528
20. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT (1996) Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 6:121-149
21. Fuhr U, Rost KL (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 4:109-116
22. Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, Beaune P, Janezic S, Grant D, Meyer UA, Staib AH (1996) Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6:159-176
23. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230
24. Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, Zanger UM, McLachlan AJ (2006) Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 80:75-84
25. Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K (2003) Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther 74:326-333
26. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K (2005) Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 77:553-559
27. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J (2005) Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 44:1209-1225
28. Shon JH, Yoon YR, Kim KA, Lim YC, Lee KJ, Park JY, Cha IJ, Flockhart DA, Shin JG (2002) Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 12:111-119
29. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA (2003) Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 43:84-91
30. Lee CR, Hawke RL, Pieper JA (2005) Twenty-four hour tolbutamide plasma concentration as a phenotypic measure of CYP2C9 activity. Eur J Clin Pharmacol 61:315-316
31. Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ (1990) Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 47:403-411
32. Jetter A, Kinzig-Schippers M, Skott A, Lazar A, Tomalik-Scharte D, Kirchheiner J, Walchner-Bonjean M, Hering U, Jakob V, Rodamer M, Jabrane W, Kasel D, Brockmoller J, Fuhr U, Sorgel F (2004) Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol 60:165-171
33. Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA (2002) Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes. Clin Pharmacol Ther 72:562-571
34. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:358-363
35. Niioka T, Uno T, Sugimoto K, Sugawara K, Hayakari M, Tateishi T (2007) Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration. Eur J Clin Pharmacol 63:1031-1038
36. Tamminga WJ, Wemer J, Oosterhuis B, Brakenhoff JP, Gerrits MG, de Zeeuw RA, de Leij LF, Jonkman JH (2001) An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19. Eur J Clin Pharmacol 57:143-146
37. Wandel C, Bocker RH, Bohrer H, deVries JX, Hofmann W, Walter K, Kleingeist B, Neff S, Ding R, Walter-Sack I, Martin E (1998) Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally. Drug Metab Dispos 26:110-114
38. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64:133-143
39. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653
40. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM (1994) Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271:549-556
41. Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, Huang SM (2009) Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 49:351-359
42. Peters SA, Schroeder P, Giri N, Dolgos H (2012) Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development. Drug Metab Dispos 40(8):1495-1507
43. Yang Z, Vakkalagadda B, Shen G, Ahlers CM, Has T, Christopher LJ, Kurland JF, Roongta V, Masson E, Zhang S (2012) Inhibitory effect of ketoconazole on the pharmacokinetics of amMultireceptor tyrosine Kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations. J Clin Pharmacol. doi: 10.1177/0091270011439208